RP 62203, A 5-Hydroxytryptamine2 Antagonist, Enhances Deep NREM Sleep in Rats | Zendy

JeanMarie Stutzmann | Zendy; B. Eon | Zendy; Michelle Lucas | Zendy; JeanCharles Blanchard | Zendy; PierreM. Laduron | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

RP 62203, A 5-Hydroxytryptamine2 Antagonist, Enhances Deep NREM Sleep in Rats

Author(s) -

JeanMarie Stutzmann,

B. Eon,

Michelle Lucas,

JeanCharles Blanchard,

PierreM. Laduron

Publication year - 1992

Publication title -

sleep

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.222

H-Index - 207

eISSN - 1550-9109

pISSN - 0161-8105

DOI - 10.1093/sleep/15.2.119

Subject(s) - non rapid eye movement sleep , agonist , wakefulness , context (archaeology) , sleep (system call) , antagonist , medicine , slow wave sleep , endocrinology , psychology , receptor , neuroscience , eye movement , biology , electroencephalography , paleontology , computer science , operating system

RP 62203, a naphtosultam derivative, is an antagonist at the 5-hydroxytryptamine2 (HT2) receptor. The sleep pattern of rats treated orally with RP 62203 was studied at doses ranging from 0.5 to 4 mg/kg. Following RP 62203 administration, the duration of deep nonrapid eye movement (NREM) sleep was found to increase at the expense of wakefulness in a dose-dependent manner from 0.5 mg/kg. The 5-HT2 receptor agonist DOI and the 5-HT1a receptor agonist 8 OH-DPAT induced a dose-related increase in wakefulness; treatment with RP 62203 reversed the enhancement of wakefulness produced by DOI but not that produced by 8 OH-DPAT. These data provide further evidence for the involvement of 5-HT2 receptors in the regulation of NREM sleep in rats. RP 62203 could therefore be of clinical interest in the management of sleep disorders, particularly those developing within a psychiatric context.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research